The 2nd Hawaii Global Summit on Thoracic Malignancies is a five-day meeting comprising seven four-hour sessions with presentations by over 50 key opinion leaders. This summit assembles translational researchers, clinical researchers, and key community oncologists to address and discuss challenges in the rapidly developing area of lung cancer and the evolution of treatment approaches.

Featuring didactic lectures, panel discussions, and case presentations highlighting individual patient challenges and new approaches designed to overcome these challenges, the summit reviews compelling data on the effects of novel strategies. There has been an explosion of new information from research on novel targeted agents for ALK+ NSCLC, new tumor driver mutations, emerging roles for immunotherapy, updated guidance for liquid biopsy, rationale for MRD testing, and overcoming resistance to current therapies.

Presentations will be given by leading experts in the field of lung cancer who will offer further insight during questionand-answer sessions. The challenges encountered in clinical management will be addressed in highly interactive sessions. In addition to these leading experts, fellows and junior faculty will have the opportunity to present and discuss their abstracts. Finally, industry representatives will showcase their data on emerging therapies that will be developed in the lung cancer space.

The Summit will review, cultivate, discuss and debate on the clinical and practical changes that will occur over the next five years in the following areas of thoracic oncology: Immunotherapy and immune checkpoint inhibitors, Approved and emerging tyrosine kinase inhibitors and other targeted agents, Emerging antibody drug conjugates, antibodies, and CAR-T therapy, and Small cell lung cancer and mesothelioma.